Patents by Inventor Kris WANG

Kris WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Effective dosages of an adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis in humans, and compositions comprising the same
    Patent number: 12714755
    Abstract: The disclosure relates to pharmaceutical compositions and methods of using pharmaceutical compositions comprising effective dosages of an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoarthritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-1 receptor antagonist (IL-1Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (IL-1Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (IL-1Ra) gene within synovial cells is regulated by an inflammation-sensitive promoter.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: August 25, 2026
    Assignee: Pacira Therapeutics, Inc.
    Inventors: Scott Kelley, Rebecca Senter, Monika Chabicovsky, Emily Walsh Martin, Neil Bodick, Won Hong, Kris Wang, Mark Douglas, John Derek Jackson
  • EFFECTIVE DOSAGES OF AN ADENOVIRAL-BASED BIOLOGICAL DELIVERY AND EXPRESSION SYSTEM FOR USE IN THE TREATMENT OF OSTEOARTHRITIS IN HUMANS, AND COMPOSITIONS COMPRISING THE SAME
    Publication number: 20220403415
    Abstract: The disclosure relates to pharmaceutical compositions and methods of using pharmaceutical compositions comprising effective dosages of an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoarthritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-1 receptor antagonist (IL-1Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (IL-1Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (IL-1Ra) gene within synovial cells is regulated by an inflammation-sensitive promoter.
    Type: Application
    Filed: September 18, 2020
    Publication date: December 22, 2022
    Inventors: Scott KELLEY, Rebecca SENTER, Monika CHABICOVSKY, Emily Walsh MARTIN, Neil BODICK, Won HONG, Kris WANG, Mark DOUGLAS, John Derek JACKSON